首页> 外文期刊>The Journal of Antibiotics: An International Journal >New Insights into Rifamycin B Biosynthesis: Isolation of Proansamycin B and 34a-Deoxy-rifamycin W as Early Macrocyclic Intermediates Indicating Two Separated Biosynthetic Pathways
【24h】

New Insights into Rifamycin B Biosynthesis: Isolation of Proansamycin B and 34a-Deoxy-rifamycin W as Early Macrocyclic Intermediates Indicating Two Separated Biosynthetic Pathways

机译:利福霉素B生物合成的新见解:分离大前霉素B和34a-脱氧利福霉素W作为早期大环中间体,表明两种分离的生物合成途径

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Proansamycin B, the formerly postulated intermediate of rifamycin B biosynthesis, was isolated from cultures of the Amycolatopsis mediterranei mutant F1/24. The structure was determined using UV, IR, NMR and MS techniques. Biotransformation studies demonstrate that proansamycin B is an intermediate of a shunt pathway, a 8-deoxy variant, of rifamycin B biosynthesis leading to 8-deoxy-rifamycin B as the final product. In addition, 34a-deoxy-rifamycin W, the direct precursor of rifamyicn W, could be isolated representing the earliest macrocyclic interemdiate obtained so far in the biosynthetic route to rifamycin B. Furthermore, the new rifamycin W-28-desmethyl-28-carboxy and rifamycin W-hemiacetal, intermediates in the transformation sequence of rifamycin W to rifamycin S, were isolated. Application of proton NMR measurements (double resonance and ROESY experiments) on the latter compound indicated that the stereochemistry at the chiral center CC-28 is R.
机译:以前假定的利福霉素B生物合成中间体Proansamycin B从Amycolatopsis mediterranei突变体F1 / 24的培养物中分离得到。使用UV,IR,NMR和MS技术确定结构。生物转化研究表明,前阿霉素B是利福霉素B生物合成分流途径(8-脱氧变体)的中间产物,最终产物为8-脱氧-利福霉素B。此外,可以分离出利福霉素W的直接前体34a-脱氧利福霉素W,这是迄今为止在利福霉素B的生物合成途径中获得的最早的大环中间体。此外,新的利福霉素W-28-去甲基-28-羧基分离出利福霉素W向利福霉素S的转化序列中的中间体利福霉素W-半缩醛。对后一种化合物进行质子NMR测量(双共振和ROESY实验)表明,手性中心CC-28的立体化学为R。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号